PETcision Co., Ltd.

寵訊生醫股份有限公司

寵訊生醫成立於2023年，專注於寵物癌症基因檢測與大數據應用，致力於打造世界領先的寵物精準醫療平台。核心產品「癌識優」運用液態切片與次世代基因定序（NGS）技術，僅需抽血即可偵測犬隻癌症，協助早期發現、治療追蹤與復發監測，具備準確、安全、早期偵測等優勢，目前已導入百餘家動物醫院並完成臨床驗證。團隊結合癌症生物學、基因資料分析、臨床獸醫與商業策略等跨領域專長，並積極建構寵物癌症基因資料庫與AI預測模型，拓展新藥開發、保險與健康管理等應用，為寵物醫療產業帶來創新突破。

PETcision is a veterinary precision medicine company building the world’s first AI-powered canine cancer genomic database. Our core product, PETcision Guard, is a liquid biopsy test that detects cancer in dogs from a simple blood draw, enabling early detection and treatment monitoring. By integrating NGS, AI-driven mutation analysis, and clinical data, PETcision provides insights for veterinarians while creating high value across industries, driving innovations in personalized pet healthcare.